SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-009381 to Ascend Wellness Holdings, Inc. (AAWH)

Ascend Wellness Holdings, Inc.
Date: Aug. 25, 2023 · CIK: 0001756390 · Accession: 0000000000-23-009381

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-274149

Date
August 25, 2023
Author
Daniel Neville
Form
UPLOAD
Company
Ascend Wellness Holdings, Inc.

Letter

United States securities and exchange commission logo August 25, 2023 Daniel Neville Chief Financial Officer Ascend Wellness Holdings, Inc. 1411 Broadway, 16th Floor New York, NY 10018 Re:Ascend Wellness Holdings, Inc. Registration Statement on Form S-3 Filed on August 22, 2023 File No. 333-274149 Dear Daniel Neville: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika N. Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: James Guttman

Show Raw Text
United States securities and exchange commission logo
August 25, 2023
Daniel Neville
Chief Financial Officer
Ascend Wellness Holdings, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
Re:Ascend Wellness Holdings, Inc.
Registration Statement on Form S-3
Filed on August 22, 2023
File No. 333-274149
Dear Daniel Neville:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tamika N. Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       James Guttman